Pharmaceuticals Company Announces Promising Results For FAP Treatment
Promising Phase 2 Results for Biodexa's eRapa(TM) Indicates Hope for FAP Patients.
Disclaimer: This article is intended for informational purposes only and should not be considered as medical advice. Please consult with a healthcare professional for medical advice and treatment options.
Biodexa Pharmaceuticals (NASDAQ:BDRX) has recently announced promising phase 2 results for its newly in-licensed drug, eRapa, aimed at treating familial adenomatous polyposis (FAP). FAP is a primarily genetic disease of the lower gastrointestinal (GI) tract for which there is currently no remedy except surgical removal of the colon and/or rectum. With a clinical trial involving 30 adult patients, three groups received the same dose of the drug but with different regimens over 12 months. The results have brought hope to FAP patients who otherwise face a 100% lifetime risk of colorectal cancer. This article delves into the details of the trial, the significance of these findings, and what the future holds for eRapa and FAP patients.
Understanding Familial Adenomatous Polyposis (FAP)
Familial adenomatous polyposis is an inherited disorder that significantly affects the gastrointestinal tract. If left untreated, it causes hundreds to thousands of polyps to develop inside the colon or rectum. This condition is typically diagnosed during the early teenage years and results in a nearly 100% lifetime risk of developing colorectal cancer. The treatment options for FAP are currently very limited. The primary remedy is the surgical removal of the colon and/or rectum, which invariably leads to the lifelong use of a colostomy bag. Given that roughly 100,000 individuals in the United States and Europe are affected by FAP, there is a substantial need for effective non-surgical interventions.
In April, Biodexa Pharmaceuticals acquired worldwide exclusive rights to eRapa, a drug that is expected to delay or even prevent the necessity for surgery in FAP patients. eRapa is a proprietary oral tablet formulation of rapamycin, a compound known for its role in regulating cellular metabolism, growth, and proliferation—factors crucial in cancer development. Using advanced nanotechnology and pH-sensitive polymers, Biodexa has designed eRapa to overcome the issues of poor bioavailability, variable pharmacokinetics, and toxicity generally associated with existing forms of rapamycin. This innovation offers a ray of hope not only for FAP patients but also potentially for those suffering from bladder and prostate cancers.
Clinical Trial Details: Phase 2 Results: The phase 2 clinical trial for eRapa involved 30 adult patients diagnosed with FAP. The participants were divided into three groups, each receiving the same dose of the drug but with different dosing regimens spread over 12 months. The primary objectives were to evaluate the safety and tolerability of eRapa and to measure changes from baseline in polyp burden using endoscopic exams.
Safety and Tolerability
After the first six months, eRapa demonstrated a favorable safety profile and was well-tolerated by patients. There were no significant adverse effects reported, which is crucial given the drug's potential long-term use in patients. The efficacy results were particularly promising. There was a statistically significant 24% reduction (p=0.04) in the total polyp burden compared to baseline measurements. Additionally, the drug showed an impressive 83% non-progression rate, indicating that it effectively halted the growth of polyps before they had the chance to turn cancerous.
These findings are groundbreaking as no other drug has shown such promise in stalling the progression of FAP. Biodexa plans to announce the 12-month results of the phase 2 trial at the InSIGHT scientific conference in Barcelona on June 19-22. Crucial to the advancement of eRapa is the financial support from the Cancer Prevention Research Institute of Texas (CPRIT), which has awarded a $17 million grant to support the phase 3 registrational study of eRapa in FAP. This grant requires a 1 for 2 match, and Biodexa has recently secured $7 million, most of the required $8.5 million match, in financing through the exercise of existing warrants. This funding will be instrumental in advancing eRapa through the final clinical stage.
What’s Next?
A phase 3 trial for eRapa is expected to commence in the first quarter of 2025. If successful, this trial could lead to applications for marketing approvals in the U.S. and Europe, bringing the drug one step closer to becoming a widely available treatment option for FAP patients. In addition to FAP, Biodexa is exploring the potential of eRapa to treat other types of cancer. An ongoing phase 2 study into the efficacy of eRapa for bladder cancer is underway, with results anticipated in the second quarter of 2025. The broad applicability of eRapa could revolutionize how multiple types of cancer are treated, making it a highly valuable asset in the pharmaceutical landscape.
The recent phase 2 trial results for Biodexa Pharmaceuticals' eRapa bring newfound hope to patients suffering from familial adenomatous polyposis, a condition that currently leaves them with few options other than invasive surgery. With its promising safety and efficacy profile, eRapa has the potential to become a groundbreaking treatment for FAP and possibly other cancers. Supported by substantial financial backing and a clear path towards phase 3 trials, the future looks bright for eRapa and the patients who may benefit from it.
Disclaimer: This article is intended for informational purposes only and should not be considered as medical advice. Please consult with a healthcare professional for medical advice and treatment options.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.